Navigation Links
Ikaria Receives Award for Excellence by New Jersey Business & Industry Association
Date:10/21/2009

CLINTON, N.J., Oct. 21 /PRNewswire/ -- Ikaria Holdings, Inc. today announced that it has been awarded the 2009 Award for Excellence in Business Expansion by the New Jersey Business & Industry Association (NJBIA), the largest state-run employer association in the United States. Ikaria earned the award based on criteria including increased productivity and revenues, as well as the net creation of new jobs.

"We are delighted that the New Jersey Business & Industry Association has recognized Ikaria for its contribution to the economic growth of New Jersey," said Daniel Tasse, Chairman and CEO of Ikaria. "This award acknowledges the strides we've made through strategic hiring of key positions in building a strong and sustainable business that is uniquely devoted to delivering novel treatments to fulfill the unmet medical needs of critically ill patients."

Ikaria was honored at the Annual NJBIA Awards Dinner on October 20, 2009.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company's lead product, INOMAX® (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America, Australia, Japan and Mexico. Ikaria is engaged in new and ongoing clinical development of INOMAX, carbon monoxide for inhalation and hydrogen sulfide. Ikaria also acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. The company also recently acquired the exclusive worldwide licenses to BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction, as well as to a portfolio of investigational compounds focused on vascular leakage for a range of critical care conditions, such as acute lung and kidney injury. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Please visit www.ikaria.com.

SOURCE Ikaria Holdings, Inc.


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
2. Ikaria(R) Named Private Company of the Year by New Jersey Technology Council
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Which areas are going to grow at the fastest ... 2026, assessing data, trends, opportunities and prospects. Our ... the most lucrative areas in the industry and the ... forecasted sales across the all the major categories of ...
(Date:1/19/2017)... SILVER SPRING, Md. , Jan. 19, 2017 ... for the treatment of Chronic Idiopathic Constipation (CIC) in adult ... patients suffering from chronic gastrointestinal disorders," said Julie Beitz ... in the FDA,s Center for Drug Evaluation and Research. "With ... select the most appropriate treatment for their condition." ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Alzheimer,s ... Leading Companies – our new study reveals trends, R&D ... and events affecting the Alzheimer,s disease therapeutics and diagnostics ... these key questions: - How is the Alzheimer,s disease ...
Breaking Medicine Technology:
(Date:1/21/2017)... Raton, FL (PRWEB) , ... January 21, 2017 , ... ... eRaiser, recently attended the January ECRM Trade Show in Hilton Head, SC, where it ... international reputation for the quality of its beauty and wellness products. At this trade ...
(Date:1/21/2017)... ... ... is the perfect set of tools for video editors that want to create the illusion ... - CEO of Pixel Film Studios. , Video editors using ProDOF can add realistic ... racking focus from one area into the next. ProDOF comes with 0.5 second, 1.0 ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites ... isolated from the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the ... key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Family Dermatology has recently joined their multi-specialty medical group. The dermatology practice ... cosmetic services. , “We’re excited to add this excellent dermatology practice to our ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, 20 ... the freedom of recovery, they often feel shame for having struggled with an eating ... (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” -- to ...
Breaking Medicine News(10 mins):